CRISPR Therapeutics CEO discounts concerns raised in an unpublished paper – The Boston Globe
|
CRISPR Therapeutics CEO discounts concerns raised in an unpublished paper
The Boston Globe SAN FRANCISCO — The new head of a genome editing company whose main research lab is in Cambridge on Tuesday brushed aside an unpublished paper that raised concerns about preexisting immune responses to the biotech's gene-editing technology, known as … |
